EditorÐI have discussed these letters with Dr Malcolm Smith, Consultant Anaesthetist. In response to Appadurai and Hanna's letter, we would make the following points.
(i) Our paper 1 is entitled`Analgesia for pelvis brachytherapy' rather than`anaesthesia'. Pain can be a major problem when patients awake from anaesthesia and the major purpose of the paper was to comment on techniques used to reduce postoperative pain. We did comment about the use of high dose brachytherapy treatments in our review (page 271), but we gave more attention to low dose rate treatments because postoperative pain is a greater problem in this group of patients. Moreover, a survey in 1994 showed that 97% of UK departments were using low dose rate apparatus, but we would acknowledge that there is a trend toward the adoption of high dose rate apparatus.
(ii) Undoubtedly, a multi-disciplinary preoperative assessment clinic is extremely useful, especially in remote stand-alone oncology units.
(iii) With the increasing use of combined chemoradiotherapy to treat carcinoma of the cervix, bone marrow suppression is an important consideration that needs to be taken into account prior to anaesthesia. However, the risk of sepsis must be balanced against tumour repopulation during the time the bone marrow is recovering. Personal experience has shown that intrauterine insertions can be carried out safely with an overall white count of 1.5±2 mm ±2 , as long as there is no pre-existing vaginal or uterine infection and the patients receive prophylactic antibiotics.
(iv) Propofol maintenance of anaesthesia is indeed a popular intraoperative technique in many disciplines. If the technique is continued via a target controlled infusion into the postoperative radiotherapy treatment phase, we would recommend the continuous presence of a trained anaesthetist, which is time and labour intensive as discussed in our article.
(v) Brachytherapy for prostate cancer is an increasing trend in the UK, although currently this is practised in only a few centres. We acknowledge that we have not dealt with this technique in our review, which is largely based on our own clinical experience and practice. It is interesting to learn that subarachnoid block provides good analgesia for this technique.
In response to Fitz-Henry and Chan's letter, although our article was primarily concerned with postoperative analgesia, we welcome their description of spinal anaesthesia for low dose rate selectron insertion, which is used in our institution in cases of obesity or respiratory disease. We very much agree with your efforts to avoid postoperative nausea and vomiting, dehydration, and promotion of multi-modal analgesia.
One of the authors (MDS) of our review 1 has studied intrathecal, diamorphine for pain relief in major bowel surgery and like many other obstetric anaesthetists, utilizes the technique for Caesarean sections. This agent would be expected to have a signi®cant analgesic effect for up to 12 h into radiotherapy treatment. However, we would stress that any elderly or medically un®t cases would require close respiratory monitoring for episodes of early respiratory depression occurring up to 6 h after spinal administration.
R. P. Symonds
Leicester, UK Management of intraoperative pulmonary oedema in a child following systemic absorption of phenylephrine eyedrops EditorÐWe read with interest the case report on intraoperative pulmonary oedema in a child following topical phenylephrine eyedrops.
1 The authors must be congratulated on achieving a successful outcome in the child. This case report highlights a welldocumented, but not a well-recognized, adverse event after topical phenylephrine.
However, we feel an opportunity was missed to highlight the correct management of the problem. This was discussed in detail by the New York State Phenylephrine Advisory Committee in its report,`New York State Guidelines on the Topical Use of Phenylephrine in the Operating Room'.
2 An important observation by this group was the role of b-blockers in the causation of pulmonary oedema and cardiac arrest after phenylephrine-induced hypertension (PIH). They looked at nine cases of PIH; ®ve of the eight patients who developed pulmonary oedema had received bblockers, either labetalol or esmolol. Of these ®ve, the three patients who had fatal cardiac arrests had received labetalol. The committee commented on the fact that only labetalol was associated with death. Because of the shorter duration of bblocking activity of esmolol, pulmonary oedema may not have progressed to cardiac arrest and death after this drug. Another review of 12 cases of cardiopulmonary compromise after topical phenylephrine, showed three cardiac arrests, all in patients who had received b-blockers as the ®rst line of treatment for PIH. 3 The recommendation was to avoid the use of b-blockers and Cachannel blockers in PIH.
When PIH occurs, a wait-and-watch policy (for 10±15 min) is recommended for mild to moderate hypertension, while for severe hypertension they recommend the use of vasodilators and ablockers, which are safer than a b-blocker. Where a b-blocker has been used, the report stressed the theoretical bene®ts of glucagon in high doses (5±10 mg), as probably the safest therapeutic option to reverse b-blocker-induced cardiac depression.
The report recommends a 0.25% solution of phenylephrine as the one of choice, and doses not exceeding 20 mg kg ±1 in children. The role of alternative vasoconstrictors like oxymetazoline, as safer alternatives, is also mentioned.
Editor±We thank Drs Kroviddi and Kulkarni for their comments. We described the rationale behind the use of labetalol in our patient with PIH in our original case report. Following phenylephrine administration, tachycardia and multifocal ventricular ectopics were observed, suggesting a b-agonist effect as well as a-mediated hypertension. The ectopics appeared to represent the most immediate threat to the patient's life, and we were reluctant to use an a-blocker because of the risk of exacerbating the tachycardia.
The New York State Guidelines were drawn up following several instances of PIH during ear, nose and throat (ENT) surgery. In the index case, involving a 4-yr-old boy, phenylephrine absorption from the site of adenoidectomy produced a degree of hypertension and tachycardia similar to that seen in our patient. Labetalol 0.12 mg kg ±1 was administered, after which pulmonary oedema, asystole and death ensued. In our own patient, labetalol 0.66 mg kg ±1 was given. It appears that we were most fortunate not to encounter more serious complications. Given our experience, the guidelines' recommendation that b-blockers should not be used for treatment of PIH would seem to apply equally in ENT and ophthalmic theatres.
However, those recommendations relating to phenylephrine concentration and dose appear to be speci®cally relevant to ENT surgery. The weakest commercially available ocular phenylephrine preparation is 2.5%. It is doubtful whether a 10-fold reduction in phenylephrine concentration would result in clinically useful pupillary dilatation. Had our surgeons used 2.5% rather than 10% phenylephrine, in keeping with the British National Formulary (BNF) recommendation 4 we cited in our case report, the dose administered to our patient would still have been more than ®ve times greater than the initial dose of 20 mg kg ±1 suggested in the New York State Guidelines.
Presumably ocular doses of this magnitude are widely deemed acceptable because phenylephrine absorption from the intact conjunctiva and nasolacrimal duct is much less than would be expected from a bleeding adenoidectomy site. In our view, the most signi®cant factor leading to excessive phenylephrine absorption in our patient was the short interval between application of the eyedrops and the conjunctival incision. Had the eyedrops been administered as prescribed, preoperatively on the ward, the complication may not have occurred. Other general preventative strategies speci®cally applicable to ophthalmic surgery were discussed in our article.
As regards a possible role for oxymetazoline, ocular phenylephrine is used to effect mydriasis rather than vasoconstriction. It is the only sympathomimetic listed for this purpose in the BNF and we are unaware of an appropriate alternative. 
A. Morley London, UK

Postoperative critical care: overnight intensive recovery
EditorÐI read with interest the editorial by Jones and Harper describing the rationale for developing the Post Operative Critical Care Unit (POCCU) in the operating theatres at the Royal Liverpool University Hospitals. 1 This elegant solution to the problems of providing short-term critical care for the surgical patient is, as they acknowledge, similar in many respects to the Overnight Intensive Recovery (OIR) concept which we have been actively promoting for a number of years.
2
The demands on the ICU are highly competitive and the elective, or even the emergency surgical, patient prioritizes poorly against other urgent or medical admissions. In our experience, the development of another existing resource, namely the recovery ward/postoperative care unit, together with the extended role of the recovery nurses, has made a signi®cant impact on reducing operative cancellation rates and waiting times for surgical procedures requiring critical care.
Another major advantage of providing short-term intensive care in a developed recovery facility (OIR) is to alleviate that demand on the ICU service and therefore increase total critical care provision within an individual hospital trust. The continuum of critical care in our trust, for example, includes the elements of the ICU, HDUs and the OIR.
I agree with Jones and Harper (and Ziser and his colleagues 3 ) who are quite correct to point out the disadvantages and dangers in the inappropriate use of an ordinary recovery ward as either an ICU over¯ow unit or an ill-equipped area pressured into providing postoperative ventilation. The formal development of beds and staf®ng within recovery to OIR or POCCU standards is essential to achieve safe critical care for the surgical patient. 4 We prefer the term Overnight Intensive Recovery as it is descriptive of the duration, function and geography of the facility. It is crucial to persuade others that this is for postoperative surgical patients only, and that it occurs in a theatre recovery ward staffed by (trained and supervised) recovery nurses and supported by anaesthetic medical staff. Although in this context critical care is probably a better term than intensive care, it has to be accepted that this OIR activity will require a 1:1 nurse:patient ratio in order to manage ventilated patients, invasive monitoring and pharmacological support.
I do take gentle issue with Jones and Harper in their assertion that the development of the OIR at St Thomas' (and more recently at Guy's) Hospital, London was only for cardiac surgical patients. It should be emphasized that cardiac surgery is not a necessary ingredient in the development of OIR beds. However, whilst it is absolutely true that the original development of cardiac fasttracking at St Thomas', and the use of the recovery ward for their postoperative management in the early 1980s, 5 led to the development of the OIR, its function then, and now, also includes a signi®cant non-cardiac workload. Currently, the annual throughput of both OIRs is around 300 non-cardiac patients, elective and emergency, from a wide number of specialties in addition to the cardiac surgical workload. Finally, our OIRs were created within rather than`adjacent to' the recovery wards, which emphasizes the ef®ciencies in staf®ng and supervision that are achieved when both general recovery and OIR areas are integral to one another. 
Submental intubation versus tracheostomy
EditorÐWhile I congratulate Mak and Ooi on their ingenious management of a patient with b-thalassaemia major undergoing maxillary and mandibular osteotomies by means of an elective submental intubation, 1 I would like to raise one important
